(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 4.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.36%.
Cormedix's revenue in 2026 is $311,709,000.On average, 9 Wall Street analysts forecast CRMD's revenue for 2026 to be $24,715,105,997, with the lowest CRMD revenue forecast at $22,814,734,501, and the highest CRMD revenue forecast at $26,020,228,018. On average, 9 Wall Street analysts forecast CRMD's revenue for 2027 to be $23,390,221,377, with the lowest CRMD revenue forecast at $20,614,762,008, and the highest CRMD revenue forecast at $26,636,030,595.
In 2028, CRMD is forecast to generate $28,071,585,768 in revenue, with the lowest revenue forecast at $24,751,469,178 and the highest revenue forecast at $31,610,671,953.